Journal Article

SREBP-1 is a novel mediator of TGF<b>β</b>1 signaling in mesangial cells

Guang Chen, Tony Wang, Lalita Uttarwar, Richard vanKrieken, Renzhong Li, Xing Chen, Bo Gao, Ayesha Ghayur, Peter Margetts and Joan C. Krepinsky

in Journal of Molecular Cell Biology

Volume 6, issue 6, pages 516-530
Published in print December 2014 | ISSN: 1674-2788
Published online October 2014 | e-ISSN: 1759-4685 | DOI: http://dx.doi.org/10.1093/jmcb/mju041
SREBP-1 is a novel mediator of TGFβ1 signaling in mesangial cells

More Like This

Show all results sharing this subject:

  • Molecular and Cell Biology

GO

Show Summary Details

Preview

Glomerular matrix accumulation is a hallmark of diabetic nephropathy. Recent studies showed that overexpression of the transcription factor SREBP-1 induces glomerulosclerosis. TGFβ1 is a key profibrotic mediator of glomerulosclerosis, but whether SREBP-1 regulates its effects is unknown. In kidney mesangial cells and in vivo, TGFβ1 activates SREBP-1. This requires SCAP, S1P, and PI3K/Akt signaling, but is independent of Smad3. Activation of the TGFβ1-responsive reporter plasmid p3TP-lux requires SREBP-1a, but not SREBP-1c, binding to an E-box adjacent to a Smad-binding element. SREBP-1a overexpression alone activates p3TP-lux. Smad3 is required for SREBP-1a transcriptional activation and TGFβ1 induces association between the two transcription factors. SREBP-1a K333 acetylation by the acetyltransferase CBP is required for Smad3 association and SREBP-1 transcriptional activity, and is also required for Smad3 transcriptional activity. Thus, both Smad3 and SREBP-1a activation cooperatively regulate TGFβ transcriptional responses. SREBP-1 inhibition provides a novel therapeutic strategy for diabetic kidney disease.

Keywords: SREBP-1; TGFβ; Smad3; fibrosis; acetylation

Journal Article.  7625 words.  Illustrated.

Subjects: Molecular and Cell Biology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.